Oncolytic viral therapies - the clinical experience

被引:238
作者
Aghi, M [1 ]
Martuza, RL [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA
关键词
oncolytic virus; clinical trials; adenovirus; herpesvirus; vaccinia virus; Newcastle disease virus;
D O I
10.1038/sj.onc.1209037
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has been 9 years since the beginning of the first clinical trial in which an oncolytic virus was administered to cancer patients. Since then, oncolytic viruses from five different species have been taken to phase I and II clinical trials in over 300 cancer patients. While additional studies will be required to ascertain if the efficacy of any of these agents is high enough to warrant adding them to the existing therapeutic regimen, it has been reassuring that DNA viruses engineered to achieve tumor selectivity and RNA viruses with relative inherent natural tumor selectivity have proven reasonably safe at the wide range of doses that were tested. Here, we review the biology and clinical results of these five species of viruses and discuss lessons learned and challenges for the future.
引用
收藏
页码:7802 / 7816
页数:15
相关论文
共 70 条
[1]  
Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO
[2]  
2-Q
[3]   A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire [J].
Batliwalla, FM ;
Bateman, BA ;
Serrano, D ;
Murray, D ;
Macphail, S ;
Maino, VC ;
Ansel, JC ;
Gregersen, PK ;
Armstrong, CA .
MOLECULAR MEDICINE, 1998, 4 (12) :783-794
[4]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[5]  
BOVIATSIS EJ, 1994, CANCER RES, V54, P5745
[6]  
BOVIATSIS EJ, 1994, GENE THER, V1, P323
[7]   The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34 [J].
Brown, SM ;
MacLean, AR ;
McKie, EA ;
Harland, J .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9442-9449
[8]   A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting [J].
Chiocca, EA ;
Abbed, KM ;
Tatter, S ;
Louis, DN ;
Hochberg, FH ;
Barker, F ;
Kracher, J ;
Grossman, SA ;
Fisher, JD ;
Carson, K ;
Rosenblum, M ;
Mikkelsen, T ;
Olson, J ;
Markert, J ;
Rosenfeld, S ;
Nabors, LB ;
Brem, S ;
Phuphanich, S ;
Freeman, S ;
Kaplan, R ;
Zwiebel, J .
MOLECULAR THERAPY, 2004, 10 (05) :958-966
[9]   Reovirus therapy of tumors with activated Ras pathway [J].
Coffey, MC ;
Strong, JE ;
Forsyth, PA ;
Lee, PWK .
SCIENCE, 1998, 282 (5392) :1332-1334
[10]   Public health: Rough-and-tumble behind Bush's smallpox policy [J].
Cohen, J ;
Enserink, M .
SCIENCE, 2002, 298 (5602) :2312-+